The effect of catheter-directed thrombolytic use on readmission rates and in-hospital outcomes among cancer patients with venous thromboembolism in the United States.
The effect of catheter-directed thrombolytic use on readmission rates and in-hospital outcomes among cancer patients with venous thromboembolism in the United States.
- 2020
BACKGROUND: Cancer inducing a hypercoagulable state, venous thromboembolism (VTE) remains a leading cause of morbidity and mortality globally. We assessed the impacts of cancer on the likelihood for readmission after a VTE-targeted procedure. CONCLUSION: The use of CDL does not appear to reduce the risk of returning for a VTE-related admission in cancer. Copyright (c) 2020 Wiley Periodicals, Inc. METHODS: We created a new cohort using discharge-level data from all hospitalizations from State Inpatient Databases of geographically dispersed participating states (18-27 states). RESULTS: In those presenting with VTE during index-admission (619 241), 2.4% patients underwent catheter directed thrombolytic therapy (CDL) on index admission and among those 20.3% had cancer. Moreover, the 30-day readmission rate amongst CDL recipients (10 776 overall) was 14.3% in those with cancer compared to 8.8% in those with no cancer history (P < .0001). Additionally, in-hospital mortality (5.7% vs 1.1%; P = 0.009) and cost-of-care (
English
0886-0440
10.1111/jocs.14444 [doi]
*Hospital Mortality
*Mechanical Thrombolysis/ae [Adverse Effects]
*Mechanical Thrombolysis/mt [Methods]
*Neoplasms/co [Complications]
*Patient Readmission/sn [Statistics & Numerical Data]
*Venous Thromboembolism/mo [Mortality]
*Venous Thromboembolism/th [Therapy]
Catheters
Cohort Studies
Costs and Cost Analysis
Female
Humans
Male
Middle Aged
United States/ep [Epidemiology]
Venous Thromboembolism/ec [Economics]
MedStar Heart & Vascular Institutena
MedStar Washington Hospital Center
Medicine/Internal Medicine
Journal Article
BACKGROUND: Cancer inducing a hypercoagulable state, venous thromboembolism (VTE) remains a leading cause of morbidity and mortality globally. We assessed the impacts of cancer on the likelihood for readmission after a VTE-targeted procedure. CONCLUSION: The use of CDL does not appear to reduce the risk of returning for a VTE-related admission in cancer. Copyright (c) 2020 Wiley Periodicals, Inc. METHODS: We created a new cohort using discharge-level data from all hospitalizations from State Inpatient Databases of geographically dispersed participating states (18-27 states). RESULTS: In those presenting with VTE during index-admission (619 241), 2.4% patients underwent catheter directed thrombolytic therapy (CDL) on index admission and among those 20.3% had cancer. Moreover, the 30-day readmission rate amongst CDL recipients (10 776 overall) was 14.3% in those with cancer compared to 8.8% in those with no cancer history (P < .0001). Additionally, in-hospital mortality (5.7% vs 1.1%; P = 0.009) and cost-of-care (
English
0886-0440
10.1111/jocs.14444 [doi]
*Hospital Mortality
*Mechanical Thrombolysis/ae [Adverse Effects]
*Mechanical Thrombolysis/mt [Methods]
*Neoplasms/co [Complications]
*Patient Readmission/sn [Statistics & Numerical Data]
*Venous Thromboembolism/mo [Mortality]
*Venous Thromboembolism/th [Therapy]
Catheters
Cohort Studies
Costs and Cost Analysis
Female
Humans
Male
Middle Aged
United States/ep [Epidemiology]
Venous Thromboembolism/ec [Economics]
MedStar Heart & Vascular Institutena
MedStar Washington Hospital Center
Medicine/Internal Medicine
Journal Article